Characterization of New Drug’s
Safety Profile Before Marketing
§ Most drugs approved by FDA with average
of 1500 patient exposures
§ Some drugs have rare toxicity profiles
(bromfenac hepatotoxicity 1 in 20,000
patients)
§ For drugs with rare toxicity, more than
100,000 patients must be exposed to generate
a signal i.e. after drug is marketed